| Literature DB >> 29499134 |
Tao Zhang1, Yen-Ching Wu1, Patrick Mullane1, Yon Ju Ji1, Honghe Liu1, Lu He1, Amit Arora1, Ho-Yon Hwang1, Amelia F Alessi2, Amirhossein G Niaki3, Goran Periz1, Lin Guo4, Hejia Wang4, Elad Elkayam5, Leemor Joshua-Tor5, Sua Myong3, John K Kim2, James Shorter4, Shao-En Ong6, Anthony K L Leung7, Jiou Wang8.
Abstract
MicroRNA-mediated gene silencing is a fundamental mechanism in the regulation of gene expression. It remains unclear how the efficiency of RNA silencing could be influenced by RNA-binding proteins associated with the microRNA-induced silencing complex (miRISC). Here we report that fused in sarcoma (FUS), an RNA-binding protein linked to neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), interacts with the core miRISC component AGO2 and is required for optimal microRNA-mediated gene silencing. FUS promotes gene silencing by binding to microRNA and mRNA targets, as illustrated by its action on miR-200c and its target ZEB1. A truncated mutant form of FUS that leads its carriers to an aggressive form of ALS, R495X, impairs microRNA-mediated gene silencing. The C. elegans homolog fust-1 also shares a conserved role in regulating the microRNA pathway. Collectively, our results suggest a role for FUS in regulating the activity of microRNA-mediated silencing.Entities:
Keywords: AGO2; ALS; Argonaute; C. elegans; FTD; FUS; RNA; gene silencing; microRNA; neurodegeneration
Mesh:
Substances:
Year: 2018 PMID: 29499134 PMCID: PMC5836505 DOI: 10.1016/j.molcel.2018.02.001
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970